D-1294-2019 Class II Terminated
FDA drug recall D-1294-2019 was initiated by MALLINCKRODT PHARMACEUTICALS on May 13, 2019 and is designated Class II. Reason for recall: Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct… The recall status is terminated (terminated Jul 17, 2023). Affected quantity: 89,808 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- May 29, 2019
- Initiation Date
- May 13, 2019
- Termination Date
- Jul 17, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 89,808 bottles
Product description
Amitiza (lubiprostone) capsules, 8 mcg, 60-count bottle, Rx only, Manufactured by: Sucampo Pharma Americas, LLC, NDC 64764-080-60
Reason for recall
Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained only 8 mcg capsules, this incident is being considered as a labeling mix-up issue.
Distribution pattern
US Nationwide
Code information
Lot #: 3229691-61, Exp 01/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1294-2019
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026